Advertisement News Archives - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

News

October 18, 2019

Trastuzumab deruxtecan granted FDA priority review to treat patients with HER2-positive metastatic breast cancer

AstraZeneca and Daiichi Sankyo announced that the US Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for [fam-] trastuzumab deruxtecan (DS-8201) and granted priority review.

Trastuzumab deruxtecan granted FDA priority review to treat patients with HER2-positive metastatic breast cancer